MARKET

LXRX

LXRX

Lexicon PHARM
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.710
-0.150
-3.09%
Opening 14:19 09/20 EDT
OPEN
4.690
PREV CLOSE
4.860
HIGH
4.750
LOW
4.590
VOLUME
328.14K
TURNOVER
--
52 WEEK HIGH
9.65
52 WEEK LOW
1.030
MARKET CAP
680.47M
P/E (TTM)
12.18
1D
5D
1M
3M
1Y
5Y
Lexicon Pharmaceuticals to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
THE WOODLANDS, Texas, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s president and chief executive officer, will present virtually at the Oppenheimer Fall Healthcare Life Science...
GlobeNewswire · 5d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Benzinga · 08/30 13:01
EDU, TAL and MMAT among pre market gainers
Vinco Ventures (NASDAQ:BBIG) +65%. Aterian (NASDAQ:ATER) +52%. Support.com (NASDAQ:SPRT) +45%. Affirm Holdings (NASDAQ:AFRM) +40% as Amazon to integrate pay-over-time into its cart Globalstar (NYSE:GSAT) +36% on report iPhone 13 may use satellite connectiv...
Seekingalpha · 08/30 12:31
Lexicon Welcomes New ESC Heart Failure Treatment Guidelines Establishing SGLT Inhibitors as Standard of Care
New guidelines from the European Society of Cardiology recommend addition of SGLT inhibitors to standard of care for patients with acute and chronic heart failure. Guidance underscores the benefits of SGLT inhibitors in significantly reducing risk of death...
GlobeNewswire · 08/30 11:00
60 Biggest Movers From Yesterday
Gainers Vinco Ventures, Inc. (NASDAQ: BBIG) shares rose 80.9% to close at $5.30 on Friday. The company recently reported a Q2 loss of $5.13 per share.
Benzinga · 08/30 09:18
--Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating
MT Newswires · 08/30 08:57
Lexicon Pharmaceuticals' Sotagliflozin Shows Reduction in Heart Issues in Diabetes Patients
MT Newswires · 08/23 14:00
Lexicon Touts Analyses From Two Phase 3 Trials Of Its Heart Failure Drug
Benzinga · 08/23 13:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of LXRX. Analyze the recent business situations of Lexicon PHARM through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average LXRX stock price target is 12.50 with a high estimate of 20.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 173
Institutional Holdings: 122.88M
% Owned: 85.05%
Shares Outstanding: 144.47M
TypeInstitutionsShares
Increased
41
4.22M
New
21
1.19M
Decreased
26
3.71M
Sold Out
23
1.28M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.59%
Pharmaceuticals & Medical Research
-1.34%
Key Executives
Chairman/Independent Director
Raymond Debbane
President/Chief Executive Officer/Director
Lonnel Coats
Chief Financial Officer/Executive Vice President
Jeffrey Wade
Executive Vice President
Alan Main
Senior Vice President
Craig Granowitz
Vice President - Finance
James Tessmer
Vice President/General Counsel
Brian Crum
Independent Director
Philippe Amouyal
Independent Director
Samuel Barker
Independent Director
Robert Lefkowitz
Independent Director
Alan Nies
Independent Director
Frank Palantoni
Independent Director
Christopher Sobecki
Independent Director
Judith Swain
No Data
About LXRX
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of treatments for human disease. The Company's drug programs include Sotagliflozin and LX9211. The Company also has a number of additional compounds into various stages of clinical and preclinical development. The Company’s LX9211 is an orally-delivered small molecule compound that is being developed for the treatment of neuropathic pain. The Company intends to initiate a Phase IIa clinical trial evaluating the safety and tolerability of LX9211 and its effects on diabetic peripheral neuropathic (DPN) pain. Its Sotagliflozin is an orally-delivered small molecule compound that is being developed for the treatment of type I diabetes and type II diabetes, heart failure and chronic kidney disease.

Webull offers kinds of Lexicon Pharmaceuticals, Inc. stock information, including NASDAQ:LXRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LXRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LXRX stock methods without spending real money on the virtual paper trading platform.